A combined SGLT1/SGLT2 inhibitor may be the next addition to the armamentarium of drugs for patients with diabetes. Deepak Bhatt, MD, MPH, will explain why and take a comprehensive look at data from recent clinical trials of sotagliflozin from 10:15 a.m. – 12:15 p.m. ET.
Next at #ADA2021: Researchers will provide new data from SCORED and SOLOIST trials
